Mesenchymal Stem Cells Derived from Human Urine-Derived iPSCs Exhibit Low Immunogenicity and Reduced Immunomodulatory Profile
Open Access
- 27 September 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10394
Abstract
Human-induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (iMSCs) represent a promising and renewable cell source for therapeutic applications. A systematic evaluation of the immunological properties and engraftment potential of iMSCs generated from urine-derived iPSCs is lacking, which has impeded their broader application. In this study, we differentiated urine-derived iPSCs into iMSCs and assessed their fundamental MSC characteristics, immunogenicity, immunomodulatory capacity and in vivo engraftment. Compared to umbilical cord-derived MSCs (UCMSCs), iMSCs demonstrated an enhanced proliferative capacity, a higher level of regenerative gene expression, and lower immunogenicity, strengthening resistance to apoptosis induced by allogeneic peripheral blood mononuclear cells (PBMCs) and the NK-92 cell line. In addition, iMSCs exhibited a diminished ability to inhibit T cell proliferation and activation compared with UCMSCs. Transcriptomic analyses further revealed the decreased expression of immune regulatory factors in iMSCs. After transfusion into mouse models, iMSCs engrafted in the lungs, liver, and spleen and exhibited the ability to migrate to tumor tissues. Our results indicated that iMSCs generated from urine-derived iPSCs have a significant replicative capacity, low immunogenicity and unique immunomodulatory properties, and hence offer obvious advantages in immune privilege and allogenic therapeutic application prospects.Keywords
Funding Information
- National Natural Science Foundation of China (82271752, 2022YFC2703402, 2022YFC2703604, 1053320212407)
- National Key Research and Development Program of China (82271752, 2022YFC2703402, 2022YFC2703604, 1053320212407)
- Fundamental Research Funds for the Central Universities of Central South University (82271752, 2022YFC2703402, 2022YFC2703604, 1053320212407)
This publication has 51 references indexed in Scilit:
- Single-Cell Transcriptomic Analysis Reveals the Cellular Heterogeneity of Mesenchymal Stem CellsGenomics, Proteomics & Bioinformatics, 2022
- Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical usesCellular and Molecular Life Sciences, 2020
- Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells Are Functionally and Genetically Different From Bone Marrow-Derived Mesenchymal Stromal CellsStem Cells, 2019
- Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease ModelStem Cells Translational Medicine, 2018
- EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinomaMolecular and Cellular Biochemistry, 2017
- Insensitivity of Human iPS Cells-Derived Mesenchymal Stem Cells to Interferon-γ-induced HLA Expression Potentiates Repair Efficiency of Hind Limb Ischemia in Immune Humanized NOD Scid Gamma MiceStem Cells, 2015
- Injectable Cultured Bone Marrow–Derived Mesenchymal Stem Cells in Varus Knees With Cartilage Defects Undergoing High Tibial Osteotomy: A Prospective, Randomized Controlled Clinical Trial With 2 Years' Follow‐upArthroscopy, 2013
- Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton’s Jelly and bone marrow sourcesCellular Immunology, 2010
- Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal CellsStem Cells, 2009
- Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescent ImagingStem Cells, 2009